Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Hematology and Stem Cell Transplantation Section, Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center and Veterans Affairs Medical Center, Nashville, Tennessee.
Biol Blood Marrow Transplant. 2017 Oct;23(10):1614-1621. doi: 10.1016/j.bbmt.2017.06.006. Epub 2017 Jun 15.
Recipients of hematopoietic cell transplantation (HCT) are at risk for potentially preventable infectious complications because of defects in humoral and cell-mediated immunity. Studies of vaccine immunogenicity in HCT recipients have shown that antibody response rates depend on age, type of vaccine, and presence or absence of graft-versus-host disease. However, few large-scale studies have assessed the immune response to vaccination in HCT recipients. Additionally, HCT recipients have much higher rates of potentially preventable infections compared with the general population even after vaccination. This review evaluates the available studies and our view on the measurement of specific antibody titers, definition of an immune response, and durability of response in HCT recipients in both inactivated and live attenuated vaccines.
接受造血细胞移植（HCT）的患者由于体液和细胞介导免疫缺陷而面临潜在可预防的感染性并发症的风险。对 HCT 受者疫苗免疫原性的研究表明，抗体反应率取决于年龄、疫苗类型以及移植物抗宿主病的存在与否。然而，很少有大规模的研究评估 HCT 受者接种疫苗后的免疫反应。此外，即使在接种疫苗后，与一般人群相比，HCT 受者发生潜在可预防感染的风险更高。这篇综述评估了现有研究，并就 HCT 受者在灭活和减毒活疫苗中特定抗体滴度的测量、免疫反应的定义以及反应的持久性提出了我们的看法。
